Journal of the Association of Physicians of India · 2022 · 10 citations · 13 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPreventive CardiologyCardiac MedicationsCardiac PharmacotherapyCardiovascular DiseaseCardiovascular PharmacologyHeart FailureSodium-glucose Cotransporter 2 InhibitorsAngiotensin Ii Receptor BlockersAngiotensin Receptor Neprilysin InhibitionAngiotensin Receptor-neprilysin InhibitorsCongestive Heart Failure ManagementHeart Failure BiomarkersRenin-angiotensin System InhibitorsSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
Heart failure with preserved ejection fraction (HFpEF) accounts for 15-20% of patients with heart failure (HF) in India. Diagnosis is by clinical features supported by biomarkers and echocardiography. Lifestyle modifications, control of risk factors to optimum levels, and treatment of comorbidities are essential in the management of HFpEF. Spironolactone and sacubitril-valsartan [angiotensin receptor neprilysin inhibitor (ARNI)] are beneficial in subsets of HFpEF, especially with lower range of ejection fraction (EF). Sodium-glucose co-transporter-2 inhibitors (SGLT2i)-empagliflozin and dapagliflozin and probably sotagliflozin are the only currently available drugs which have shown benefits in HFpEF, mostly by reducing hospitalizations. The benefit of SGLT2i is evident in both diabetic and nondiabetic subsets.
13
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker, Javed Butler, Gerasimos Filippatos et al. · New England Journal of Medicine · 2021 · 4.6K citations · Full text
Medicine, Cardiology, Pharmacology +14
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Cardiology, Pharmacology +16